INTERVIEW
Osamu Takeguchi, Managing Director, Life Science Practice Lead, Consulting Business
When customers have a problem, we want to be the person they think of first.
Osamu TakeguchiManaging Director, Life Science Practice Lead, Consulting Business
― Please tell us about your responsibilities.
After working as a product manager in the marketing department of a foreign healthcare company and a foreign pharmaceutical company, he entered the consulting world and provided consulting services specializing in pharmaceutical companies at a major firm. Leveraging that experience, he is currently managing director of INTLOOP Strategy, where he primarily provides strategic consulting services to pharmaceutical companies. He is also involved in recruiting freelance talent with knowledge and consulting experience in the pharmaceutical industry.
― What do you think are the advantages of INTLOOP Strategy?
The pharmaceutical industry is highly specialized, and without a certain level of industry knowledge, discussions with clients will not be meaningful. However, there are not many consultants with such knowledge and experience, and it is common for companies to simply hire anyone. INTLOOP, on the other hand, has over 49,000 registered freelance consultants, many of whom possess industry knowledge and expertise. By effectively assigning these consultants and combining them with our own capabilities, we can provide pharmaceutical companies with even greater value. We believe this is our greatest advantage and strength.
INTLOOP also has a development team, so INTLOOP Strategy can focus on upstream strategic consulting with clients, and then hand over the reins to INTLOOP itself once the support phase moves to building IT systems and data infrastructure. This system of close and consistent collaboration, from strategy to quality, would be difficult to establish even for a major consulting firm.
― What do you think about the company’s future prospects and growth potential?
There’s no doubt that the declining birthrate and aging population will continue, making it increasingly difficult to secure specialized, work-ready personnel. Meanwhile, the challenges faced by companies, not just pharmaceutical companies, are becoming increasingly complex and sophisticated. In this context, I believe that a system that can arrange specialized freelance personnel is a major strength, even from the perspective of future prospects and growth. Building on this strength, my current major goal is to establish a clear brand within the industry as INTLOOP Strategy’s life science practice. To achieve this, it’s essential that we go beyond one-off support and earn your trust as a partner that supports mid- to long-term corporate transformation. I aim to establish a team that will be the first person pharmaceutical companies think of when they have a problem.
(Publish date: September 29, 2025)
Other Interviews
-
- Tackling problem solving from three perspectives: consulting, investment, and innovation
- Shota Fujikawa Representative Director and CEO
View All
-
- Aiming to speed up Services cycles through the synergy of consulting and innovation
- Takashi Tojo Head of Innovation Business / Managing Director, High-Tech Practice Lead, Consulting Business
View All
-
- From a major foreign company to a small but elite team – A career at INTLOOP Strategy where you can “challenge what you want to do”
- Kengo Shibuya Managing Director, Telecom Practice Lead, Consulting Business
View All